Table 4. Important studies signifying the role of RIT in lymphoma.

Immuno or radioimmuno conjugate	Population and N	Results	Reference
Rituximab	Relapsed low grade or follicular NHL, N=166	ORR: 48%; CRR: 6%; Projected median TTP for responders: 13m	McLaughlin et al., 1998 [22]
Rituximab + CHOP vs. CHOP	Aggressive NHL, N=399; randomized study	76% vs. 63%; Higher event free and overall survival rate, reduced risk of treatment failure and death	Coiffer et al., 2000 [23]
Zevalin	Rituximab refractory follicular NHL, N=54	ORR: 74%; CR: 15%; Overall TTP: 6.8m	Witzig et al., 2002 [30]
Zevalin vs. Rituximab	Relapsed or refractory follicular, low-grade, or transformed NHL; N=143; randomized multicenter study	ORR: 80% vs. 56%; CR: 30% vs. 16%; TTP and median DR: no significant difference	Witzig et al., 2002 [24]
Zevalin after chemotherapeutic induction of a CR or PR vs. control group	Advanced stage follicular lymphoma in first remission, N=414; multicenter randomized study	Median PFS of 36.5m vs. 13.3m; 77% of PR cases converted to CR with Zevalin	Morschauer et al., 2008 [25]
Bexxar vs. tositumomab	Relapsed or refractory NHL, N=78; randomized trial	ORR: 55% vs. 19; CR: 33% vs. 8%	Davis et al., 2003 [27]
Bexxar vs. salvage chemotherapy	Low grade or transformed low-grade NHL, N=60	ORR: 65% vs. 28%; CR: 17% vs. 3%	Kaminski et al., 2001 [26]
Bexxar	Relapsed or refractory low-grade, follicular, or transformed low-grade NHL, N=250; integrated efficacy analysis of the previous five clinical trials	ORR: 47% - 68%; CR: 20% - 38%; 5-year PFS: 17%	Fischer et al., 2005 [31]
Bexxar	Stage III or IV follicular lymphoma, N=76	ORR: 95%; CR: 75%; 5-yr PFS: 59%	Kaminski et al., 2005 [28]
Bexxar after short course of Fludarabine	Early stage, N=35	ORR: 98%; Median PFS > 48m	Leonard et al., 2005 [29]

ORR: Overall objective response rate; CR: Complete response; PR: Partial response; PFS: Progression free survival; TP: Time to progression; DR: Duration of response; m: months